MARKHAM, ON & SAN DIEGO, CA – Astellas Pharma has entered into a research collaboration with GenomeDx Biosciences to use latter’s Decipher® Classifier and Decipher GRID® as a potential aid for genomic tumor profiling and to better identify which prostate cancer patients would respond to treatment with XTANDI® (enzalutamide).
As part of the agreement, Astellas will provide GenomeDx with tumour samples from its Phase 2 ENACT trial (NCT02799475), which is comparing the time to prostate cancer progression between patients treated with enzalutamide versus patients undergoing active surveillance. GenomeDx will profile all samples and provide Astellas with an analysis of tumour aggressiveness based on its Decipher Classifier score, and a Decipher GRID profile which will assess the biological behavior of a patient’s tumor based on a set of signatures that may be associated with enzalutamide response.
“Profiling our study samples through Decipher Classifier and Decipher GRID will provide us with expansive genomic information, allowing Astellas to potentially deliver innovative, targeted therapies to patients most likely to benefit,” said Dr. Bruce Brown, senior medical director, oncology at Astellas. “The genomic data provided by GenomeDx will help us to better understand the molecular drivers of prostate cancer and how those drivers interact with response to enzalutamide.”
According to Dr. Doug Dolginow, CEO of GenomeDx, GenomeDx’s Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumours from patients with urological cancers, and ranks among the largest shared genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases using cloud-based analytics.
Derived from GRID, GenomeDx’s Decipher Prostate Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumour aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, and Decipher Post-Op is indicated for men after prostate removal surgery.